Latest Developments
ProStrakan Reports Further Strong Progress in Preclose
Update – 1/8/2008
ProStrakan Group plc today issues a business and trading update
for the 12 months ended 31 December, 2007, ahead of the close
period preceding the publication of the Group's Preliminary
Results, planned for March 13, 2008.
Click
to view more
Positive US Phase III Interim Data on Rapinyl™ Released
by Endo Pharmaceuticals Inc. - 12/17/2007
Galashiels, Scotland, 17 December, 2007 – ProStrakan
Group plc (LSE: PSK), the international specialty pharmaceutical
company, announces that Endo Pharmaceuticals Inc. (“Endo”)
has today reported positive results from an interim statistical
analysis of its US Phase III, placebo-controlled, double-blind
trial of Rapinyl™ (announcement attached). Rapinyl™ is a
fast-dissolving tablet for sublingual administration of fentanyl
intended for the treatment of breakthrough cancer pain. ProStrakan
has in-licensed the exclusive rights to develop and market Rapinyl™
in Europe from Orexo AB, while Endo has in-licensed the rights
for North America.
Click
to view more
Peter Allen Takes Up Position as Chairman of ProStrakan
- 12/7/2007
ProStrakan Group plc, the international specialty pharmaceutical
company, announced on October 30, 2007 that its co-founder and
Chairman, Harry Stratford OBE, had informed the Board of his
intention to retire as Chairman at the end of 2007. The
Company also announced that Peter Allen, a Non-Executive Director
since 2005, had accepted the Board’s invitation to replace
him. ProStrakan announces that the formal handover took place
at the Company’s Board meeting, which was held yesterday
(December 6, 2007).
Click
to view more
ProStrakan Receives Approval for Adcal-D3 Dissolve™
- 12/3/2007
ProStrakan Group plc (LSE: PSK), the international specialty
pharmaceutical company, today announces that it has received
approval from the Medicines and Healthcare products Regulatory
Agency (MHRA) for the launch in the UK of Adcal-D3 Dissolve™
1500mg/400IU Effervescent Tablets™ – a new soluble formulation
of its market-leading calcium vitamin D supplement, Adcal-D3™.
Click
to view more
Peter Allen to Succeed Harry Stratford as Chairman
of ProStrakan - 10/30/2007
ProStrakan Group plc (LSE: PSK) today announces that its founder
and Chairman, Harry Stratford OBE, has informed the Board of
his intention to retire as Chairman at the end of 2007. Peter
Allen, a Non-Executive Director since 2005, has accepted the
Board’s invitation to become Chairman from that point.
Click
to view more
ProStrakan to Establish US Sales Force Through Strategic
Alliance With NovaQuest - 10/22/2007
ProStrakan announces the formation of a strategic alliance with
NovaQuest to commercialize ProStrakan products in the United
States of America.
Click
to view more
Regulatory Update - 9/28/2007
ProStrakan Group plc (LSE: PSK), the international specialty
pharmaceutical company, today provides the market with an
update on the progress of a number of products undergoing
EU approvals processes following yesterday’s EMEA meetings: · Rapinyl™
EU Approval Process Enters Extended Phase · Droperidol™
Receives EU Approval.
Click
to view more
Interim Results for the Six Months Ended June 30, 2007 – 9/12/2007
ProStrakan Group plc, the international pharmaceutical company,
today announces its interim results for the six months ended
June 30, 2007.
Click
to view more
ProStrakan Announces Commencement of Recruitment in
Pivotal US Trials for Fortigel™ (Tostran™) and Cellegesic (Rectogesic™) – 8/20/2007
ProStrakan Group plc (LSE: PSK), the specialty pharmaceutical
company, today announces the enrolment of the first patients
into two pivotal US trials in pursuit of FDA approval for its
products: Fortigel™ (branded Tostran™ in most of Europe) and Cellegesic
(branded Rectogesic™ in Europe).
Click
to view more
ProStrakan Announces LG Life Sciences as South Korean
Partner for SANCUSO™ - 8/13/2007
ProStrakan
Group plc (LSE: PSK), the European specialty pharmaceutical
company, today announces that it has signed an exclusive distribution
agreement with LG Life Sciences, Ltd. (“LGLS”),
a leading pharmaceutical company in South Korea, for SANCUSO™,
ProStrakan’s transdermal granisetron patch for the prevention
of chemotherapy-induced nausea and vomiting.
Click
to view more
ProStrakan Launches Nordic Sales Joint Venture With
Orexo – 8/1/2007
ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical
company, announces that it has entered into a joint venture
agreement with the Swedish pharmaceutical company Orexo AB (OMX
Midcap: ORX) to collaborate in the marketing and distribution
of the current and future product portfolios of both ProStrakan
and Orexo in the Nordic countries (Norway, Sweden, Finland,
Denmark & Iceland).
Click
to view more
ProStrakan Reports Strong Revenue Growth in Preclose
Trading Update – 7/5/2007
ProStrakan Group plc, the European specialty pharmaceutical
company, today issues a business and trading update for the
six months ending June 30, 2007, ahead of the close period preceding
the publication of the Group's Interim Results, planned for
September 12, 2007.
Click
to view more
UK Launch of ProStrakan's Latest Pan EU Product - Tostran™ – 6/11/2007
ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical
company, today announces the UK launch of Tostran™ - the latest
in a sequence of existing and planned pan-European products.
Click
to view more
ProStrakan Appoints New Chief Financial Officer – 4/17/2007
ProStrakan announces today that it has appointed Paul Garvey
as Chief Financial Officer.
Click
to view more
Preliminary Results for Year Ended 31 December 2006 – 3/28/2007
Main features: revenue up 22% to £38.5m; gross profit
up by 39% to £23m; SANCUSO™ to be filed for regulatory
approval during 2007, Tostran™ and Rectogesic™ successfully completed
EU regulatory approval; Rapinyl™ and Droperidol™ submitted for
EU approval.
Click
to view more
ProStrakan Announces £50 Million Debt Facility – 3/28/2007
ProStrakan announces today that it has entered into a £50
million debt facility with the initial advance being provided
by funds managed by Fortress Investment Group, Morgan Stanley
and funds managed by Och-Ziff Capital Management Group. The
Administrative Agent is Morgan Stanley Bank International Limited.
Click
to view more
ProStrakan Appoints Callum Spreng as Communications
Director – 2/12/2007
Spreng will join ProStrakan in April from media group SMG plc
where he has been Communications Director since 1998. He
will be responsible for strategic communications with the group’s
investors, City analysts, business press, specialist press and
staff.
Click
to view more
